109467 20230519145512.0 doi 10.3390/jcm10163494 sideral 125525 ART-2021-125525 eng Marco-Benedí, Victoria Universidad de Zaragoza Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins 2021 Access copy available to the general public Unrestricted Background: Cataracts are the main cause of blindness and represent one fifth of visual problems worldwide. It is still unknown whether prolonged statin treatment favors the development of cataracts. We aimed to ascertain the prevalence of cataract surgery in elderly subjects with genetically diagnosed heterozygous familial hypercholesterolemia (HeFH) receiving statin treatment for ≥5 years, and compare this with controls. Methods: This is an observational, multicenter, case–control study from five lipid clinics in Spain. We collected data with the following inclusion criteria: age ≥65 years, LDL cholesterol levels ≥220 mg/dL without lipid-lowering drugs, a pathogenic mutation in a candidate gene for HeFH (LDLR, APOB, or PCSK9) and statin treatment for ≥5 years. Controls were selected from relatives of HeFH patients without hypercholesterolemia. Linear and logistic regressions based on generalized linear models and generalized estimating equations (GEE) were used. Cataract surgery was used as a proxy for cataract development. Results: We analyzed 205 subjects, 112 HeFH, and 93 controls, with a mean age of 71.8 (6.5) and 70.0 (7.3) years, respectively. HeFH subjects presented no difference in clinical characteristics, including smoking, hypertension, and type 2 diabetes mellitus, compared with controls. The mean duration of lipid-lowering treatment in HeFH was 22.5 (8.7) years. Cataract surgery prevalence was not significantly different between cases and controls. The presence of cataracts was associated neither with LDLc nor with the length of the statin therapy. Conclusion: In the present study, HeFH was not a risk factor for cataract surgery and prolonged statin treatment did not favor it either. These findings suggest that statin treatment is not related with cataracts. info:eu-repo/grantAgreement/ES/ISCIII-MINECO/PI19-00694 info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 4.964 2021 MEDICINE, GENERAL & INTERNAL 55 / 172 = 0.32 2021 Q2 T1 1.04 2021 Medicine (miscellaneous) 2021 Q1 4.4 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Laclaustra, Martín Universidad de Zaragoza (orcid)0000-0003-3963-0846 Sánchez-Hernández, Rosa M. Ortega-Martínez de Victoria, Emilio Pedro-Botet, Juan Puzo, Jose Universidad de Zaragoza (orcid)0000-0002-1309-4363 Civeira, Fernando Universidad de Zaragoza (orcid)0000-0001-7043-0952 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 10, 16 (2021), 3494 [5 pp.] J. clin.med. Journal of Clinical Medicine 2077-0383 225463 http://zaguan.unizar.es/record/109467/files/texto_completo.pdf Versión publicada 2685578 http://zaguan.unizar.es/record/109467/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:109467 articulos driver 2023-05-18-15:12:10 ARTICLE